% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Forget:137641,
      author       = {A. Forget and L. Martignetti and S. Puget and L. Calzone
                      and S. Brabetz$^*$ and D. J. Picard$^*$ and A. Montagud and
                      S. Liva and A. Sta and F. Dingli and G. Arras and J. Rivera
                      and D. Loew and A. Besnard and J. Lacombe and M. Pagès and
                      P. Varlet and C. Dufour and H. Yu and A. L. Mercier and E.
                      Indersie and A. Chivet and S. Leboucher and L. Sieber$^*$
                      and K. Beccaria and M. Gombert and F.-D. Meyer$^*$ and N.
                      Qin$^*$ and J. Bartl$^*$ and L. Chavez$^*$ and K.
                      Okonechnikov and T. Sharma$^*$ and V. Thatikonda$^*$ and F.
                      Bourdeaut and C. Pouponnot and V. Ramaswamy and A.
                      Korshunov$^*$ and A. Borkhardt and G. Reifenberger and P.
                      Poullet and M. D. Taylor and M. Kool$^*$ and S. Pfister$^*$
                      and D. Kawauchi$^*$ and E. Barillot and M. Remke$^*$ and O.
                      Ayrault},
      title        = {{A}berrant {ERBB}4-{SRC} {S}ignaling as a {H}allmark of
                      {G}roup 4 {M}edulloblastoma {R}evealed by {I}ntegrative
                      {P}hosphoproteomic {P}rofiling.},
      journal      = {Cancer cell},
      volume       = {34},
      number       = {3},
      issn         = {1535-6108},
      address      = {Cambridge, Mass.},
      publisher    = {Cell Press},
      reportid     = {DKFZ-2018-01521},
      pages        = {379 - 395.e7},
      year         = {2018},
      abstract     = {The current consensus recognizes four main medulloblastoma
                      subgroups (wingless, Sonic hedgehog, group 3 and group 4).
                      While medulloblastoma subgroups have been characterized
                      extensively at the (epi-)genomic and transcriptomic levels,
                      the proteome and phosphoproteome landscape remain to be
                      comprehensively elucidated. Using quantitative
                      (phospho)-proteomics in primary human medulloblastomas, we
                      unravel distinct posttranscriptional regulation leading to
                      highly divergent oncogenic signaling and kinase activity
                      profiles in groups 3 and 4 medulloblastomas. Specifically,
                      proteomic and phosphoproteomic analyses identify aberrant
                      ERBB4-SRC signaling in group 4. Hence, enforced expression
                      of an activated SRC combined with p53 inactivation induces
                      murine tumors that resemble group 4 medulloblastoma.
                      Therefore, our integrative proteogenomics approach unveils
                      an oncogenic pathway and potential therapeutic vulnerability
                      in the most common medulloblastoma subgroup.},
      cin          = {B062 / L401 / G380 / L101},
      ddc          = {610},
      cid          = {I:(DE-He78)B062-20160331 / I:(DE-He78)L401-20160331 /
                      I:(DE-He78)G380-20160331 / I:(DE-He78)L101-20160331},
      pnm          = {319H - Addenda (POF3-319H)},
      pid          = {G:(DE-HGF)POF3-319H},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:30205043},
      doi          = {10.1016/j.ccell.2018.08.002},
      url          = {https://inrepo02.dkfz.de/record/137641},
}